drugset / Trial / NCT00444678
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
Phase 2
Completed
36 enrolled
NYU Langone Health
Bristol-Myers Squibb · collabEli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase II, open label, non-randomized study in subjects with histologically confirmed diagnosis of advanced KRAS wild type adenocarcinoma of the colon or rectum, who have not received prior chemotherapy for metastatic disease.
Timeline
- Start
- 2004-06-01
- Primary completion
- 2012-08-01
- Completion
- 2015-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 2500 mg | Oral |
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |